Cargando…

Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces

Antibody-Framework-to-Antigen Distance (AFAD) – the distance between the body of an antibody and a protein antigen – is an important parameter governing antibody recognition. Here, we quantify AFAD for ~2,000 non-redundant antibody-protein-antigen complexes in the Protein Data Bank. AFADs showed a g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Myungjin, Changela, Anita, Gorman, Jason, Rawi, Reda, Bylund, Tatsiana, Chao, Cara W., Lin, Bob C., Louder, Mark K., Olia, Adam S., Zhang, Baoshan, Doria-Rose, Nicole A., Zolla-Pazner, Susan, Shapiro, Lawrence, Chuang, Gwo-Yu, Kwong, Peter D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578620/ https://www.ncbi.nlm.nih.gov/pubmed/34753907 http://dx.doi.org/10.1038/s41467-021-26579-z

Ejemplares similares

Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies
por: Cottrell, Christopher A., et al.
Publicado: (2021)

Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site
por: Banach, Bailey B., et al.
Publicado: (2023)

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
por: Zhang, Baoshan, et al.
Publicado: (2023)

Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies
por: Wei, Qing, et al.
Publicado: (2020)

Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design
por: Holt, Graham T., et al.
Publicado: (2023)

Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies
por: Frey, Gary, et al.
Publicado: (2010)

Identifying epitopes of HIV-1 that induce protective antibodies
por: Zolla-Pazner, Susan
Publicado: (2004)

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
por: Cerutti, Gabriele, et al.
Publicado: (2021)

HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide
por: Wang, Shuishu, et al.
Publicado: (2023)

P20-09. Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies
por: Swetnam, J, et al.
Publicado: (2009)

Improvement of antibody functionality by structure-guided paratope engraftment
por: Liu, Qingbo, et al.
Publicado: (2019)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
por: Kwon, Young D., et al.
Publicado: (2023)

Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases
por: Olia, Adam S., et al.
Publicado: (2023)

Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV
por: Dingens, Adam S., et al.
Publicado: (2018)

Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates
por: Rawi, Reda, et al.
Publicado: (2019)

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
por: Shi, Wei, et al.
Publicado: (2022)

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
por: Shi, Wei, et al.
Publicado: (2022)

Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
por: Almond, David, et al.
Publicado: (2012)

Residue 315 regulates V3 exposure and V3 antibody recognition on HIV subtype B and C viruses
por: Manhas, S, et al.
Publicado: (2012)

Impact of IgG Isotype on the Induction of Antibody-Dependent Cellular Phagocytosis of HIV by Human Milk Leukocytes
por: Fox, Alisa, et al.
Publicado: (2022)

Human Natural Antibodies Recognizing Glycan Galβ1-3GlcNAc (Le(C))
por: Dobrochaeva, Kira, et al.
Publicado: (2020)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
por: Kwon, Young D., et al.
Publicado: (2021)

Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV
por: Zolla-Pazner, Susan, et al.
Publicado: (2019)

Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies
por: Chuang, Gwo-Yu, et al.
Publicado: (2020)

Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations
por: Upadhyay, Chitra, et al.
Publicado: (2018)

Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers
por: Yang, Zhi, et al.
Publicado: (2022)

Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2016)

Crystal structure analysis of anti-V2 mAb 2158 suggests a conformational epitope involving an N-linked glycan
por: Spurrier, B, et al.
Publicado: (2012)

Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies
por: Amin, Mohammed N., et al.
Publicado: (2013)

A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77
por: Chen, Xi, et al.
Publicado: (2017)

Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses
por: Chuang, Gwo-Yu, et al.
Publicado: (2021)

Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity
por: Mayr, Luzia M., et al.
Publicado: (2017)

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

Epitope Mapping of Conformational V2-specific Anti-HIV Human Monoclonal Antibodies Reveals an Immunodominant Site in V2
por: Mayr, Luzia M., et al.
Publicado: (2013)

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody
por: Kwon, Young D., et al.
Publicado: (2018)

Biophysical dissection of the antigen-antibody interaction of the broadly reactive anti-V3 human mAb 447-52D
por: Killikelly, A, et al.
Publicado: (2012)

Generation of a monoclonal antibody recognizing the CEACAM glycan structure and inhibiting adhesion using cancer tissue-originated spheroid as an antigen
por: Sato, Yumi, et al.
Publicado: (2016)

Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies
por: Williams, Wilton B., et al.
Publicado: (2021)

Characterization of H type 1 and type 1 N-acetyllactosamine glycan epitopes on ovarian cancer specifically recognized by the anti-glycan monoclonal antibody mAb-A4
por: Choo, Matthew, et al.
Publicado: (2017)

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies
por: Davis-Gardner, Meredith E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b2iorpmvv93usrafj9nk1fuuv6